Deutsche Bank Has Buy on Allergan

Deutsche Bank is out with a research report on Allergan (NYSE: AGN) and it has a Buy rating and a $97 price target on shares.

In a note to clients, Deutsche Bank writes, "Allergan has established itself as a premier global company in eye and skin care pharmaceuticals, as well as medical aesthetics. We remain impressed with its broad diversification across products and geographies and its mix of reimbursed versus cash-pay businesses. Given these attributes and sustainability of its revenue base - increasingly a rarity among companies in specialty pharma - we continue to rate the company's shares Buy post Q3 results."

Shares of AGN lost $3.22 yesterday to close at $83.74, a loss of 3.7%.